OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$12.05
+0.25 (+2.12%)
Open$11.93
Previous Close$11.80
Day High$12.21
Day Low$11.87
52W High$36.26
52W Low$4.47
Volume—
Avg Volume860.9K
Market Cap1.05B
P/E Ratio—
EPS$-2.03
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+39.5% upside
Current
$12.05
$12.05
Target
$16.81
$16.81
$15.48
$16.81 avg
$21.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |
| Rev Growth | +22.4% | +21.1% | -4.4% |
| Debt/Equity | 0.25 | 0.24 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |